Company News
ADC Therapeutics Shares Plunge 45.9%
ADC Therapeutics SA shares fell 45.9% in after‑hours trading after Phase 3 LOTIS‑5 topline results were released.
Trial met primary endpoint with median PFS 6.1 months vs 4.7 months, ORR 58.1% vs 45.2
